Back to top
more

Surgery Partners (SGRY)

(Real Time Quote from BATS)

$24.20 USD

24.20
94,314

-0.64 (-2.58%)

Updated Apr 26, 2024 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

SGRY vs. DOCS: Which Stock Is the Better Value Option?

Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Company News for Feb 27, 2024

by Zacks Equity Research

Companies in The News Are: DPZ,FRPT,SGRY,ITRI

The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum

by Zacks Equity Research

Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum are part of the Zacks top Analyst Blog.h

Sanghamitra Saha headshot

Warren Buffett's Annual Letter: Key Insights for Investors

by Sanghamitra Saha

Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).

Here's What Key Metrics Tell Us About Surgery Partners (SGRY) Q4 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Surgery Partners (SGRY) Beats Q4 Earnings Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 18.92% and 0.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Gear Up for Surgery Partners (SGRY) Q4 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

InnovAge Holding Corp. (INNV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Surgery Partners (SGRY) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.

Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.

Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls

by Zacks Equity Research

Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

Abbott's (ABT) Q4 Earnings Match Estimates, Margins Rise

by Zacks Equity Research

Abbott (ABT) delivers better-than-expected revenues and in-line earnings for the fourth quarter of 2023.

Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?

by Zacks Equity Research

Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.

Compared to Estimates, Surgery Partners (SGRY) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Surgery Partners (SGRY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Surgery Partners (SGRY) Soars 9.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Surgery Partners (SGRY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surgery Partners (SGRY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina

by Zacks Equity Research

Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.

Select Medical (SEM) Up 18% Year to Date: More Room to Run?

by Zacks Equity Research

Select Medical (SEM) is well-poised for growth on the back of a credible healthcare facility portfolio built through buyouts and JVs coupled with strong cash-generating abilities.

Zacks Industry Outlook Highlights Medpace, HealthEquity and Surgery Partners

by Zacks Equity Research

Medpace, HealthEquity and Surgery Partners are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks Countering Industry-Wide Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and SGRY are set to gain the most. However, staffing shortages may disrupt the trend.

Down -22.17% in 4 Weeks, Here's Why Surgery Partners (SGRY) Looks Ripe for a Turnaround

by Zacks Equity Research

Surgery Partners (SGRY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.